SCNI

Scinai Immunotherapeutics Ltd ADR

1.66

Sep 11 • 3:59 PM ET -0.01 (-0.60%)

2.04

Aftermarket • 7:59 PM ET +0.38 (22.89%)

Healthcare Biotechnology Israel Nano NASD

Sep 11, 4:30 PMScinai's Sep 8 refocus on NanoAb platform and CDMO growth sparks delayed after-hours buying

Peers: APRE GOVX KAPA BCDA BIVI CALC CVM KPRX LNAI NEUP

Scroll to Statements

Index	-
Market Cap	1.18M
Enterprise Value	7.54M
Income	-2.67M
Sales	1.50M
Book/sh	10.71
Cash/sh	4.01
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	45
IPO	May 12, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	0.79
P/B	0.15
P/C	0.41
P/FCF	-
EV/EBITDA	-
EV/Sales	5.03
Quick Ratio	1.56
Current Ratio	1.56
Debt/Eq	0.31
LT Debt/Eq	0.27
Option/Short	No / Yes

EPS (ttm)	-47.55
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	51.07% 21.04%
Sales past 3/5Y	- -
EPS Y/Y TTM	-165.46%
Sales Y/Y TTM	30.12%
EPS Q/Q	79.16%
Sales Q/Q	144.95%
Earnings	Aug 24 BMO
EPS/Sales Surpr.	- -

Insider Own	2.25%
Insider Trans	0.00%
Inst Own	2.69%
Inst Trans	-
ROA	-18.38%
ROE	-27.22%
ROIC	-17.84%
Gross Margin	-
Oper. Margin	-435.17%
Profit Margin	-178.14%
SMA20	-30.66%
SMA50	-33.13%
SMA200	-71.58%
Trades

Shs Outstand	0.71M
Shs Float	0.69M
Short Float	1.19%
Short Ratio	0.09
Short Interest	0.01M
52W High	16.40 -89.88%
52W Low	1.60 3.75%
Volatility	8.18% 12.44%
ATR (14)	0.29
RSI (14)	27.97
Beta	2.13
Rel Volume	36.21
Avg Volume	96.49K
Volume	3,493,695

Perf Week	-14.87%
Perf Month	-32.79%
Perf Quarter	-48.94%
Perf Half Y	-77.26%
Perf YTD	-76.69%
Perf Year	-89.49%
Perf 3Y	-98.72%
Perf 5Y	-99.93%
Perf 10Y	-99.96%
Recom	1.00
Target Price	7000.00
Prev Close	1.67
Price	1.66
Change %	-0.60%

Sep-08-26 09:18AM	Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business (PR Newswire) -8.60%
Aug-24-26 07:00AM	Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum (PR Newswire)
Aug-10-26 06:34AM	Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration (PR Newswire)
Jun-10-26 07:55AM	Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives (PR Newswire) -7.71%
May-20-26 07:00AM	Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility (PR Newswire) -6.02%
08:05AM	Loading…
May-15-26 08:05AM	Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe (PR Newswire)
Apr-24-26 08:00AM	Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing (PR Newswire) +61.62%
Apr-06-26 07:00AM	Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities (PR Newswire)
Apr-01-26 07:35AM	Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration (PR Newswire) +12.12%
Mar-19-26 07:50AM	Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring 2026 (PR Newswire)
Mar-16-26 04:05PM	Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price (PR Newswire)
Mar-02-26 09:20AM	Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised 12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept (PR Newswire)
Feb-25-26 08:11AM	Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform (PR Newswire) +5.94%
Feb-17-26 07:00AM	Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm (PR Newswire)
Jan-07-26 07:00AM	Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL (PR Newswire)
08:50AM	Loading…
Dec-02-25 08:50AM	Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances (PR Newswire)
Oct-06-25 07:30AM	Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities (PR Newswire)
Sep-02-25 07:30AM	Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet (PR Newswire)
Jul-29-25 07:15AM	Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN (PR Newswire)
Jun-26-25 07:37AM	Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology" (PR Newswire)
Jun-12-25 08:00AM	Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025 (PR Newswire)
Jun-05-25 09:00AM	Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. (PR Newswire) +28.97%
May-30-25 07:00AM	Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn (PR Newswire)
May-07-25 04:01PM	Scinai Announces Annual Financial Results for 2024 (PR Newswire)
May-01-25 07:00AM	Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases (PR Newswire)
Mar-27-25 09:25AM	Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions (PR Newswire) -14.83%
Mar-17-25 07:00AM	Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025 (PR Newswire)
Mar-05-25 07:30AM	SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT (PR Newswire)
Jan-06-25 07:31AM	Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences (PR Newswire)
Dec-16-24 09:25AM	Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc. (PR Newswire)
08:25AM	Loading…
Dec-05-24 08:25AM	Prof. Michael Schn, Director of Dermatology and Venereology at the University Medical Center Gttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board (PR Newswire)
Nov-27-24 08:00AM	Dr. Jonathan Sadeh, Former Senior Vice President of Immunology RandD at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board (PR Newswire)
08:00AM	Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board (PR Newswire)
Nov-22-24 07:15AM	Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million (PR Newswire) +17.22%
Oct-31-24 06:59AM	Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024 (PR Newswire)
Sep-16-24 07:00AM	Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies (PR Newswire)
Sep-09-24 11:12AM	IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. (GlobeNewswire) -7.46%
Aug-29-24 06:31AM	Scinai Regains Full Compliance with Nasdaq Listing Requirements (PR Newswire)
Aug-21-24 08:45AM	Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000 (PR Newswire)
Aug-20-24 09:30AM	Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder (PR Newswire)
Aug-15-24 07:00AM	Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23 (PR Newswire)
Aug-13-24 07:00AM	Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity (PR Newswire)
Aug-05-24 06:30AM	7 F-Rated Stocks for Your August 2024 Sell List (InvestorPlace) -6.76%
Jul-23-24 07:00AM	Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb (PR Newswire)
Jul-15-24 12:41PM	PLUG Stock Alert: Plug Power Gets Approval for HyVia Acquisition (InvestorPlace) +45.07%
12:22PM	M Stock Plunges 13% as Macy's Calls Off Take-Private Talks (InvestorPlace)
12:04PM	Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today? (InvestorPlace)
07:00AM	Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model (PR Newswire)
Jul-08-24 08:14AM	Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity (PR Newswire)
Jul-03-24 09:32AM	Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements (PR Newswire)
Jul-02-24 01:52PM	SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q1 2024 (InvestorPlace)
08:12AM	Scinai Publishes Q1 2024 Financial Results and Provides Business Update (PR Newswire)
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -8.16%
Jun-17-24 07:56AM	Why Is Scinai Immunotherapeutics (SCNI) Stock Up 88% Today? (InvestorPlace) +60.46%
07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jun-13-24 07:00AM	Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity (PR Newswire)
Jun-07-24 07:00AM	Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement (PR Newswire) -28.41%
Jun-03-24 10:52AM	SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q4 2023 (InvestorPlace) -5.33%
May-24-24 04:01PM	Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance (PR Newswire) +12.46% -9.42%
May-15-24 04:01PM	Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update (PR Newswire)
May-06-24 09:21AM	Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal (PR Newswire)
Apr-10-24 07:00AM	Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schn of UMG (PR Newswire)
Apr-08-24 07:00AM	Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services (PR Newswire)
Mar-12-24 08:00AM	Scinai leadership to attend BIO-Europe Spring 2024 (PR Newswire)
Feb-29-24 08:45AM	Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024 (PR Newswire)
Feb-13-24 07:00AM	Scinai Welcomes Liat Halpert as Head of Business Development and Sales (PR Newswire)
Jan-25-24 10:26AM	Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Grlich on Louis-Jeantet Prize (PR Newswire)
Jan-04-24 04:01PM	Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds (PR Newswire) -5.84%
06:15AM	Scinai Immunotherapeutics CEO Issues Letter to Shareholders (PR Newswire)
Dec-29-23 09:21AM	Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds (PR Newswire) -14.93%
Dec-27-23 07:15AM	Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9 (PR Newswire) +9.35%
Dec-20-23 08:05AM	Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors (GlobeNewswire)
Dec-12-23 07:26AM	Scinai Announces Promising Results in a Psoriatic Human Skin Model (PR Newswire) -5.71%
Dec-11-23 08:11AM	Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug (PR Newswire)
Nov-29-23 09:25AM	European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031 (PR Newswire) +7.14%
Nov-20-23 07:30AM	Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule (PR Newswire) -6.35%
Nov-06-23 07:30AM	Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit (GlobeNewswire)
Nov-03-23 04:30PM	Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance (GlobeNewswire)
Oct-31-23 09:00AM	European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai's recent strategic pivot (GlobeNewswire)
08:23AM	Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 07:00AM	Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023 (GlobeNewswire)
Oct-04-23 07:30AM	Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023 (GlobeNewswire) -6.13%
Sep-19-23 04:05PM	Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering (GlobeNewswire)
Sep-15-23 09:01AM	Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering (GlobeNewswire) -15.52%
Sep-13-23 04:13PM	Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results (GlobeNewswire) -11.45%
Sep-11-23 07:30AM	Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston (GlobeNewswire)
Sep-06-23 06:00AM	BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics (GlobeNewswire)
Aug-11-23 09:00AM	BiondVax Reports Second Quarter Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-23 04:01PM	Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules (GlobeNewswire)
Jul-11-23 08:17AM	IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (GlobeNewswire)
Jun-05-23 07:00AM	BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis (GlobeNewswire) -10.00%
May-30-23 06:00AM	BVXV: Developing anti-IL-17 NanoAb (Zacks Small Cap Research)
May-15-23 04:45PM	BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update (ACCESSWIRE)
Apr-17-23 04:25PM	BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update (GlobeNewswire) +20.11% -9.30%
Mar-16-23 01:10PM	BiondVax to Present at BIO-Europe Spring (GlobeNewswire) +7.44%
Mar-06-23 01:31PM	IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman (NewMediaWire)
Mar-03-23 02:07PM	IBN Announces Test. Optimize. Scale. Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes (GlobeNewswire)
Feb-02-23 02:15PM	BiondVax Presenting at BIO CEO & Investor Conference (GlobeNewswire)
Jan-23-23 11:50AM	BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate (Benzinga)
06:25AM	BiondVaxs Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study (GlobeNewswire)

Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.

MBAAmir Reichman

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCNI

Scinai Immunotherapeutics Ltd ADR

Upgrade your Finviz experience